TSH Biopharm Corporation Limited (TPEX:8432)

TSH Biopharm Corporation Revenue

TSH Biopharm Corporation had revenue of 557.20M TWD in the quarter ending September 30, 2026, with 31.86% growth. This brings the company's total for the last twelve months to 1.53B, up 20.56% year-over-year. In the year 2025, TSH Biopharm Corporation had annual revenue of 1.34B with 19.79% growth. That makes TSH Biopharm Corporation the 28,473rd largest company in the world by revenue and 1,348th in Taiwan.

• Revenue (ttm): 1.53B
• Revenue Growth: +20.56%
• P/S Ratio: 1.54
• Revenue / Employee: 20.15M
• Employees: 76
• Market Cap: 2.36B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Reinvestment Business Group 765.97M 53.8%
• Cardiovascular and Gastrointestinal Drugs Business Group 656.95M 46.2%

Fiscal year ended Dec 31, 2025 See the full TSH Biopharm Corporation breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.34B	220.81M	19.79%
Dec 31, 2024	1.12B	304.80M	37.59%
Dec 31, 2023	810.92M	69.85M	9.43%
Dec 31, 2022	741.07M	327.58M	79.23%
Dec 31, 2021	413.48M	-34.38M	-7.68%

Data Source: S&P Global Market Intelligence Last updated: Nov 3, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 7, 2026

Data Sources Report a data error